Curium to buy Lantheus in all
Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.
How this was made
The 30-second read
Why it matters
The disclosed per-share price, CVR structure, premium levels, unanimous board approval, and expected closing timeline create a tradable M&A catalyst for both the target (LNTH) and acquirer (CRMD), with key risks centered on regulatory and shareholder approvals and financing/integration execution.
Market read
A take-private M&A deal with defined consideration and CVR upside is announced, setting up deal-spread trading and approval-risk positioning through 1H 2027.
What to watch
Financing is via debt and equity, but the article provides no leverage or dilution details; integration execution and CVR milestone achievability could materially affect realized value.
Background
Curium and Lantheus are radiopharmaceutical and radiodiagnostics players; the article frames the transaction as combining Curium’s theranostics capabilities with Lantheus’ US-based radiodiagnostics business.
Ticker impact
Curium will buy all outstanding Lantheus shares for $102.50 per share, with CVRs potentially adding up to $12 more per share.
Bullish bias for LNTH on deal confirmation odds, with volatility tied to regulatory and shareholder approval through 1H 2027.
The article discloses specific consideration ($102.50 plus up to $12 CVRs), premium metrics, unanimous board approval, and expected closing window, which are direct inputs to deal-spread valuation.
Market effects
Signals consolidation in radiopharmaceuticals and theranostics, potentially increasing M&A expectations and competitive pressure for US radiodiagnostics franchises.
Strengthens Curium’s US diagnostic presence (F18-based prostate diagnostics) and neurology/echocardiography reach.
Creates a combined platform operating across more than 70 countries, potentially affecting global supply and commercial coverage in nuclear medicine.
Counterpoint
Deal spreads can widen if regulatory scrutiny or shareholder opposition emerges, so the announced premium may not fully protect downside in the interim.
Key entities
- acquirerCurium
Nasdaq-listed Curium US will purchase all outstanding Lantheus shares under the agreement.
- targetLantheus
Nasdaq-listed radiopharmaceutical company being taken private; shareholders receive $102.50 per share plus CVRs up to $12.
- executiveMary Anne Heino
Lantheus executive chair and CEO endorsing the transaction.
- executiveRenaud Dehareng
Curium CEO describing strategic fit and integration rationale.
